Supreme Court review could redefine Roundup liability for Bayer AG

Supreme Court review could redefine Roundup liability for Bayer

The U.S. Supreme Court is set to hear Monsanto Co. v. Durnell on April 27, a case that could reshape how liability for glyphosate‑based herbicides is resolved and has direct implications for Bayer AG, which acquired Monsanto in 2018. The appeal challenges a Missouri jury verdict that awarded plaintiff John Durnell $1.25 million after finding Monsanto failed to warn him that Roundup exposure allegedly caused his non‑Hodgkin lymphoma. Monsanto argues that the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) and federal pesticide labeling law preempt state failure‑to‑warn claims, seeking to limit thousands of similar suits nationwide.

The U.S. Solicitor General files a brief siding with Monsanto, warning that allowing state‑court verdicts to stand could permit juries to second‑guess science‑based determinations made by the Environmental Protection Agency, potentially disrupting a uniform federal regulatory regime. Missouri’s courts have so far upheld the liability ruling, and state legislative attempts to shield Monsanto from such suits have failed, keeping the litigation landscape uncertain for Bayer. Durnell’s lawyers contend Monsanto has known for decades about cancer risks tied to glyphosate yet marketed Roundup as safe, a claim that underpins many of the plaintiff victories across state courts.

A decision for Monsanto could steer pesticide safety disputes away from state tort litigation toward federal administrative processes, lowering Bayer’s exposure to damage awards but raising the stakes of regulatory reviews and agency determinations. Conversely, a ruling against Monsanto would preserve the ability of state juries to impose liability despite federal labeling and could encourage further state‑level suits and consumer remedies. The case thus presents both legal and business‑strategy consequences for Bayer and the broader agrochemical industry, affecting product labeling, risk management and how companies defend science and safety claims in court.

Other pending Supreme Court business

The court also schedules Chatrie v. United States for April 27 to consider whether the Fourth Amendment bars warrants that capture cellphone location histories, and will hear consolidated cases challenging in‑house Federal Communications Commission adjudications on April 21.

Regulatory and scientific backdrop

The litigation unfolds against divergent official views: the World Health Organization’s IARC classifies glyphosate as “probably carcinogenic to humans” (2015), the EPA rejects that finding, and California lists glyphosate as a cancer‑causing chemical (2017), creating a complex regulatory environment for Bayer and rivals.